An HRB Probiotic Strain for Infant Health, Gastrointestinal, and Immune Development
B. breve M-16V stands out as an Human-Residential Bifidobacteria (HRB) probiotic strain, holding significance as a key inhabitant within the gastrointestinal tract of infants. It’s widely recognized for its beneficial role in maintaining health. Notably, B. breve M-16V is a stable strain that thrives at room temperature. Renowned as one of the most rigorously researched and clinically backed probiotic strains, it stands as an ally in bolstering the healthy growth and overall well-being of infants.*
Supported by over 100 scientific studies (as of March 2023), B. breve M-16V has been a trusted choice since 1994, serving as the probiotic of choice for over 140 neonatal intensive care units (NICUs) and pediatric departments in affiliated hospitals across Japan, aiding in the healthy development of babies. In 2012, B. breve M-16V was introduced to NICUs in Australia, and more recently, it has been embraced by NICUs in New Zealand and Singapore.*
Morinaga Milk remains committed to extending the benefits of B. breve M-16V to babies and children worldwide, facilitating healthy growth and well-being.*
Explore our range of downloadable resources and gain insights into the crucial role of the gut microbiota, the thriving gut health market, and clinical studies backing B. breve M-16V.
B. breve M-16V is a valued functional ingredient in a diverse range of products. Depending on your needs, we can accommodate a variety of product requests targeted at different consumer segments and health areas.*
Legislation can be varied by country when it comes to specific dosage and potential health claims of each strain.
Our regulatory team can help and advise you as to the appropriate individual markets permit. Morinaga’s global regulatory experts are in all major regions. We are committed to delivering expert advice and practical solutions to optimize your company’s success.
The information on this website is intended exclusively for business-to-business purposes and is not intended for end-consumer utilization. It is predicated upon our rigorous research and development endeavors and, to the best of our knowledge, is deemed reliable. Morinaga disclaims any liability arising from the utilization of its products, as the terms of employment are beyond our purview. The business-oriented information furnished herein should not be construed as a substitute for professional counsel. Prior to implementation, manufacturers and marketers are advised to ascertain compliance with local regulatory prerequisites, given that divergent claims may be permissible contingent upon the prevailing regulations in individual countries. This presentation is purely informative in a scientific context and does not constitute claims or marketing notifications within the jurisdiction of the United States.
Explore the Morinaga Probiotics Center to delve into key highlights showcasing the clinical efficacy of B. breve M-16V.
Be Inspired to Innovate with HRB Probiotics
Elevate your product quality with science-backed, functional ingredients.